Alentis Therapeutics debuts with CHF12.5m
Liver specialist Alentis Therapeutics AG has raised CHF12.5m in a Series A round co-led by BioMedPartners and BB Pureos Bioventures.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
EMA recommends nine drugs for market approval
In its first meeting in Amsterdam, the CHMP of the European Medicines Agency recommended six new drugs, two orphan meds, and one biosimilar for EU market authorisation.
A Holy Grail in the quest to end cancer
Targeted therapies and chemotherapeutics have helped cut cancer deaths dramatically in the last few decades. In the US, the overall mortality rate of 251/100,000 patients in 1991 had fallen by 2016 to 156/100,000 patients. Engineered (multispecific) antibodies, cell therapies and combination therapies are expected to continue to increase success rates with primary tumors. And research groups are turning their big guns on what is now the biggest killer – metastasis.
A novel strategy against rheumatoid arthritis
Researchers at AstraZeneca, Viela Bio, Gilead Sciences, Antidote Therapeutics Inc., and at SoseiHeptares report on a new small molecule compound to treat RA.
US patent office grants Charpentier CRISPR patent
The US Patent Office has granted the Charpentier/Doudna key CRISPR patent, which was previously involved in an interference proceeding.
European Parliament greenlights Horizon Europe priorities
As a first result of the trilogue on the €100m+ Horizon Europe programme, MEPs backed the backbone of the EU’s future research and innovation programme.
Blood routine testing in sepsis and AHF ahead
Pilot routine tests with the vasoactive biomarker bio-ADM confirm clinical test results. Medical leaders back actionable utility of the marker in medical decision-making in septic shock and congestive heart failure.
Biotechpharma UAB expanding production
Lituanian CDMO Biotechpharma UAB has invested €50m in order to expand its production capacity to 5000 litres.
Kiadis Pharma NV to acquire CytoSen Therapeutics, Inc.
Kiadis Pharma NV has entered a definitive agreement to acquire US-based CytoSen Therapeutics, Inc. in order to create a leader in cell-based cancer immunotherapy.
Treating diabetes by mimicking gut bacteria effects
Researchers at University of Glasgow report that modulation of a specific GPCR results in health benefits normally mediated by a healthy gut microbiome.